

CooperCompanies

Investor Presentation

June 2, 2022

CooperVision® CooperSurgical®



Cautionary Statements

Forward-Looking Statements

This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding the effects of the ongoing of the ongoing COVID-19 pandemic, and the impact of Russia's invasion of Ukraine on our business; and statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and diluted earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the "Forward-Looking Statements" section in our press releases and under the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Non-GAAP Financial Measures

Certain financial measures included in this presentation, or which may be referred to in management's discussion of the Company's results and outlook, are non-GAAP measures that we believe are helpful in understanding our results, for example, constant currency, adjusted EBITDA, non-GAAP earnings per share and non-GAAP margin results. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Our non-GAAP financial results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. The reasons that we use these non-GAAP measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available in our Securities and Exchange Commission filings, including under the "Reconciliation of GAAP Results to Non-GAAP Results" section in our press releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com.



A Leading Medical Device Company



Improving lives one person at a time

Industry-leader in
Vision and
Women's Health

Member of the
S&P 500 since
2016



FY21 Revenue \$2.92B




12,000+
Global
Workforce

10+
Manufacturing and
Distribution Sites

100+
Countries Where
Cooper Products
Are Sold

CooperCompanies

8.2% annual sales growth from 2016 to 2021



CooperCompanies

Fiscal 2022 financial guidance

		FY22 Guidance*	Organic Growth vs. FY21
Sales	Total	\$3,280 - \$3,312	9% - 10%
	CooperVision	\$2,225 - \$2,247	10% - 11%
	CooperSurgical	\$1,055 - \$1,065	6% - 7%
EPS	Non-GAAP	\$13.09 - \$13.29	



CooperVision

A global leader dedicated to helping improve
the way people see each day




CooperVision®
Live Brightly.®




Global Soft Contact Lens Market

Market by Competitor



Market by Category



High Barriers to Entry

- High capital outlay with highly specialized manufacturing
- Technological know-how
- Stringent FDA and worldwide regulation
- Long history of product innovation (SiHy with intellectual property)


Favorable Industry Characteristics

- Strong fundamental growth drivers
- Underlying wearer growth
- Limited reimbursement risk
- Recession resistant
- Annuity business (stickiness)

The Growing Myopia Epidemic

Myopia is expected to affect half the world population by 2050

Worldwide Prevalence of Myopia



Why?



Increased
screen time



Less time
outdoors



Genetics

Risks

Significant
ocular
health
issues

Impaired
learning and
development

Impact to
quality of
everyday
life



Contact Lens Market Drivers

Strong fundamental growth drivers

- New fits/trade-up
 - Shift into 1 Day SiHy lenses
 - Growth in Torics and Multifocals
- Growing global wearer base
 - Growing prevalence of myopia
 - 1/3 of the world's population is myopic going to 1/2 by 2050
 - Geographic expansion – low emerging market penetration
- Higher net pricing



A Global Leader in Myopia Management

Broadest portfolio of science-based treatment options addressing the progression of myopia in children



MiSight® 1 day

**Only FDA approved
myopia control product**



**Broad range of market-
leading Ortho-k lenses**



SG
SIGHTGLASS
VISION

**Innovative myopia
management spectacles**

Joint Venture with EssilorLuxottica



Cooper**Companies**

MiSight[®] 1 day

First and only FDA-approved⁽¹⁾ myopia control contact lens

Business Highlights

- Launched Brilliant Futures™ Myopia Management Program with MiSight[®] in multiple countries worldwide including the U.S.
- Sold as a treatment program by practitioners
- Investing in myopia management globally including in MiSight[®]
- Preparing for a broader launch in China

Growth Drivers⁽³⁾

- Works for nearly all myopic children
- Cuts myopia progression by roughly 59% on average⁽²⁾
- Works at any age a child starts treatment
- Works for as long as the child wears it
- There is no rebound if treatment is stopped



Alan Kim, Age 9 | MiSight[®] 1 day wearer and actor




CooperCompanies

Note: (1) MiSight[®] (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia (nearsightedness) in children with non-diseased eyes, who at the initiation of use are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. (2) When compared to the children in the control group wearing a single vision 1-day contact lens. (3) As confirmed by our industry-leading, 7-year clinical study of MiSight[®].


CooperVision

History of success

Durable Sales Growth



Outpacing Market Growth




CooperVision


Revenue by product category and geography

FY21 Revenue \$2.15B

Revenue by Category



Revenue by Geography



CooperVision

Well positioned to succeed

Products



Diverse suite of best-in-class products to fit a wide range of patient needs

1 Day

FRP

Sphere

Toric

Multifocal

Toric Multifocal

Extended Ranges

Myopia Management

Specialty

Silicone Hydrogel

Hydrogel

Support



Branded and customized solutions

Logistical and distribution **excellence**

Differentiated Value-Added Services



BRILLIANT FUTURES™
WITH MIGHT™ 1 day

Relationships



Global footprint



Strong **key account** relationships

Outstanding customer experience



CooperCompanies



CooperSurgical

Healthy women, babies and families™



FY21 Revenue \$771M

Revenue by Category



CooperSurgical

Fertility portfolio well positioned for success

Business Highlights

- Broadest medical device coverage of the entire IVF cycle⁽¹⁾
- Pioneers in IVF genetic testing (state-of-the-art R&D lab)
- Closed Generate Life Science acquisition (12/17/21)
 - Enables new strategic growth opportunities – egg & sperm donation, cryopreservation
 - Increases product offerings, leverages sales force



CooperCompanies

Fertility Industry Highlights

\$1.8B+


Global Market¹

5-10%

Annual Growth

- **Growth Drivers:**
 - Increasing maternal age
 - Greater access to treatment
 - Increased patient awareness/comfort
 - Greater worldwide disposable income
- **Up to 1 in 8 couples suffer from infertility worldwide**

Medical Devices for the IVF Cycle⁽¹⁾



1. Manufacturer sales of products and services excluding consultation and pharma
Source: Management estimates and independent market research

CooperSurgical

Extensive office and surgical platform

Business Highlights

- Produce over 600 clinically-relevant medical devices used by women's health care providers in gynecology and obstetrics
- Recently closed Generate Life Science acquisition (12/17/21)
 - Expands CSI Labor & Delivery
 - Adds a well-established cord blood and cord tissue storage platform
 - Leverages CSI's highly-respected clinical/professional relationships to cross-sell and advance education
 - Solid recurring revenue stream



Industry Highlights

- **Medical Device Drivers:**
 - Shifting to minimally invasive procedures
 - Reimbursement is designed to drive procedures to the office
 - Health systems are looking for partnership relationship with vendors
- **Cord Blood and Cord Tissue Storage Drivers:**
 - Advancing stem cell research & therapies increase potential value of storage
 - Cord blood is standard of care alternative to bone marrow transplants for blood disorders¹
 - Regenerative Medicine potential applications rapidly emerging (lung disease, sports injury, etc.) with 1k+ ongoing clinical studies²

Gynecology Obstetrics

Office-based
providers

Labor &
Delivery

Operating
room



endosee ADVANCE

Paragard[™]
intrauterine copper contraceptive



INSORB[®] Skin Stapler
Absorbable | Subcuticular

RUM[®] II SYSTEM



CooperCompanies

1. Chao, N. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. In: UpToDate. Negrin, R (Ed), UpToDate, Waltham, MA.
2. <https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/> Accessed Nov 10, 2021

CooperSurgical

Office and surgical – Paragard IUD

Business Highlights

- Only US FDA-approved 100% Hormone Free Intrauterine Device (IUD)
- Over 99% effective
- One simple active ingredient – Copper
- Lasts up to 10 years with Immediate Reversibility
- In office placement
- Opportunity to create top of mind awareness




CooperCompanies

Note: Paragard is included in CooperSurgical's office and surgical category
Source: Management estimates and independent market research

IUD Industry Highlights

Paragard[®]
intrauterine copper contraceptive




Growth Drivers:

- Mid-single digit market growth
- Increased awareness and desire for a non-hormonal product
- 70% of women are concerned about hormones in birth control
- Opportunity to shift the U.S. market toward non-hormonal products

CooperSurgical

History of success



Environmental, Social, Governance (ESG)

Committed to enhancing the health and wellness of people and communities locally and globally

ENVIRONMENT

Protecting our planet and preserving resources is part of our commitment to improving lives.



6 facilities LEED® or BREEAM® certified



Prevented nearly 28 million plastic bottles from polluting the oceans through our focus on plastic neutrality



100% renewable electricity sourcing at all key facilities in New York and the United Kingdom



95% of materials in CooperVision's production processes are recycled



Launched four-part **Circularity Approach** to manage the impacts of plastic

SOCIAL

Working at CooperCompanies means being part of a purpose-driven, diverse, and dynamic team that cares about making the world a better place.



Women made up **49%** of our global workforce, while racially and ethnically diverse employees made up **35%** of our U.S. workforce



Scored **100%** on the Human Rights Campaign Foundation's 2022 Corporate Equality Index



\$1.4 million raised to date for Optometry Giving Sight, providing **eye exams for 275,000 people**



Certified as a Great Place to Work and as a Top 10 Best Large Workplace in Manufacturing and Production in the U.S.



Investing ~\$2M in **talent development** over the next three years

GOVERNANCE

Strong governance practices and high standards of ethics, compliance, and accountability provide long-term value for our shareholders, customers, employees, and communities.



50% Board gender diversity



Code of Conduct updated in 2021



\$0 monetary losses as a result of legal proceedings associated with bribery and corruption or false marketing claims



Strong information security and data privacy governance and risk management



A dedicated cross-functional ESG team, ESG Executive Steering Committee and the Board of Directors **oversee ESG Issues**



CooperCompanies

Source: Data provided is from CooperCompanies' 2021 ESG Report

Well Positioned for the Future

